What exactly is Ozempic?

Ozempic is the brand name of a medicine called semaglutide, made by the Danish pharmaceutical company Novo Nordisk. Novo Nordisk has spent more than a century working on diabetes medicines and is the company that gave the world many modern insulin products.

Semaglutide belongs to a class of drugs with an intimidating name: GLP-1 receptor agonists. In plain English, that means it copies the action of a hormone called GLP-1 (glucagon-like peptide-1) that your own intestine naturally releases every time you eat. Think of GLP-1 as your body's built-in "I have eaten, I am satisfied, please manage my sugar" signal. The problem is that this hormone breaks down in your body within minutes. Semaglutide is essentially a long-acting, lab-modified copy of the same signal that lasts an entire week from a single dose.

The U.S. Food and Drug Administration first approved Ozempic on 5 December 2017 for type 2 diabetes. Europe followed in February 2018. Doctors have now had almost a decade of real-world experience with this molecule — it isn't a 2024 invention, despite what social media suggests.

Ozempic was originally designed purely as a diabetes drug. The dramatic weight loss seen in trial volunteers was a side effect — but a side effect so striking that Novo Nordisk developed a higher-dose version specifically for obesity (we'll come to that).

How Ozempic works — three switches in your body

Most patients we meet assume Ozempic is "a fat-burner." It isn't. It doesn't chemically melt fat. What it does is flip three switches in your body that, together, make it much easier to eat less and use sugar better.

Switch 1: Your appetite brain quiets down

The hunger and fullness centres of your brain sit in a small area called the hypothalamus. GLP-1 receptors are present there. When semaglutide attaches to them, your brain receives a steady "you are full" signal even when you haven't eaten much. The constant background thinking about food that many people with weight issues describe — the so-called "food noise" — usually goes quiet within the first few weeks. You'll finish half a thali instead of a full one and feel perfectly satisfied.

Analogy: Imagine the volume knob of your "I want to eat" radio. Ozempic doesn't switch the radio off — it simply turns the volume down from 9 to 3.

Switch 2: Your stomach empties more slowly

Normally, after a meal, your stomach passes food into the intestines in about 1–2 hours. Semaglutide slows this transit. Food sits longer in the stomach, so you feel full sooner and stay full longer.

Analogy: Think of your stomach as a kitchen sink. Ozempic narrows the drain so the same amount of dal-chawal takes much longer to clear. You don't want to refill the sink until it empties.

This is also why some side effects (nausea, fullness, mild reflux) appear in the first weeks — your body is adjusting to a slower-emptying stomach.

Switch 3: Your pancreas releases insulin only when needed

The pancreas makes insulin, the hormone that lets your body use sugar. In type 2 diabetes, this system gets sluggish. Semaglutide nudges the pancreas to release more insulin — but, crucially, only when blood sugar is actually high. When your sugar is normal, semaglutide stops pushing insulin out.

This "glucose-dependent" behaviour is why semaglutide on its own almost never causes dangerously low blood sugar (hypoglycaemia) — unlike older diabetes pills such as sulphonylureas or insulin injections.

Talk to an AIIMS-trained doctor.

2-minute eligibility test. Free. We'll see if Kaivo is the right fit for you.

Ozempic vs Wegovy vs Rybelsus — same medicine, three products

All three brands contain the same molecule — semaglutide — and all three are made by Novo Nordisk. The difference lies in dose, form, and what they are officially approved for.

A few rules to remember. If a doctor recommends an injection for diabetes, you're getting Ozempic (or a generic of it). If the goal is weight management in someone without diabetes, the medically correct prescription is Wegovy, which goes up to a higher 2.4 mg dose. And Rybelsus is the tablet for needle-averse patients with T2D — taken every morning on an empty stomach with no more than 120 ml of plain water, and you must wait at least 30 minutes before eating, drinking, or taking other medicines.

For more on this molecule and brand family, see our complete semaglutide guide.

What the clinical evidence actually shows

This is where Ozempic stops being an Instagram fad and starts being one of the most studied drugs in modern medicine. Three large trials matter most.

STEP-1 (2021) — the trial that made the world pay attention

Published in The New England Journal of Medicine on 10 February 2021, the STEP-1 trial (Wilding et al.) enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related condition), none of whom had diabetes. They were randomised to weekly semaglutide 2.4 mg or placebo, with lifestyle counselling, for 68 weeks.

The results: average body weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of people on semaglutide lost at least 5% of their body weight, compared with 31.5% on placebo. For an average participant starting at around 105 kg, this meant losing roughly 15–16 kg. For a non-surgical intervention, this was unprecedented.

SUSTAIN-6 (2016) — proof of heart protection in diabetes

Published in NEJM in November 2016 (Marso et al.), SUSTAIN-6 randomised 3,297 people with type 2 diabetes at high cardiovascular risk to semaglutide or placebo over two years. The combined risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke fell by 26% (6.6% on semaglutide vs 8.9% on placebo). This was the first solid evidence that semaglutide doesn't just lower sugar — it actively reduces serious cardiac events.

SELECT (2023) — heart protection even without diabetes

Published in NEJM in November 2023 (Lincoff et al.), SELECT enrolled 17,604 adults aged 45 and over who were overweight or obese (BMI ≥27) and had established cardiovascular disease — but did not have diabetes. Over an average of 40 months: major cardiovascular events were reduced by 20%. Cardiovascular death fell by 15%; death from any cause fell by 19%. Weight loss was sustained over four years.

Based on SELECT, the FDA expanded Wegovy's label on 8 March 2024 to include cardiovascular risk reduction in people with overweight/obesity and existing heart disease — the first time any weight-loss medication has carried such a heart-protection indication.

What about regaining weight after stopping?

This is the question every Indian patient asks. The STEP-1 extension (Wilding et al., 2022) followed 327 participants for a year after stopping semaglutide. On average, they regained about 11.6 percentage points of the 17.3% they had originally lost — settling at a net loss of around 5.6% from their starting weight. Stopping suddenly does cause regain, but you do not necessarily end up where you started. Most obesity specialists now treat this as a long-term medication, much like blood pressure tablets, rather than a short course.

Who is it for — and who should avoid it?

In the West, the eligibility cut-offs are: type 2 diabetes not controlled on metformin and lifestyle; or BMI ≥30, or BMI ≥27 with at least one weight-related condition.

But Indian patients need to pay close attention. South Asians develop diabetes, fatty liver and heart disease at much lower BMIs than Europeans — the "thin-fat Indian" phenotype documented by Dr CS Yajnik and others. The revised 2025 Indian obesity guidelines (Misra et al., Diabetes & Metabolic Syndrome) define obesity in Asian Indians beginning at a BMI of 23 kg/m². For more on Indian-specific T2D, see our diabetes guide.

Who should not take Ozempic or Wegovy

There are a few hard contraindications written directly on the drug label: personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN-2); pregnancy and breastfeeding; known hypersensitivity to semaglutide; history of pancreatitis.

For a more nuanced view of the thyroid contraindication — which is widely misunderstood online — see our thyroid and weight guide, which spells out what is and isn't a contraindication.

Side effects — what to realistically expect

The vast majority of side effects are gastrointestinal, mild to moderate, dose-related, and improve over the first 2–3 months. In STEP-1, around 44% of participants reported some nausea, and overall GI side effects occurred in roughly 74% of those on semaglutide versus 48% on placebo — but most did not stop the medicine.

Common, expected: nausea (worst in the first 1–2 weeks of each new dose), vomiting, diarrhoea, constipation, abdominal discomfort, loss of appetite, fatigue, mild reflux.

Less common but serious — see a doctor immediately: severe persistent abdominal pain radiating to the back (possible pancreatitis), right-upper abdominal pain with fever or jaundice (gallbladder), significant decrease in urine output, worsening vision in people with diabetic eye disease, severe allergic reaction.

"Ozempic face": when you lose weight rapidly, facial fat pads shrink, which can make people look gaunt. This isn't specific to Ozempic — it happens with any rapid weight loss. Slower titration and adequate protein intake help. Same for hair shedding, which is a temporary phase that usually reverses within 6–9 months.

Muscle loss: up to a third of lost weight can be lean mass if you don't eat enough protein and do resistance training — a particular concern for older Indian patients and vegetarians.

Why this matters especially in India

India is currently the world's diabetes and metabolic-disease epicentre.

The landmark ICMR-INDIAB study, published in The Lancet Diabetes & Endocrinology in June 2023 (Anjana et al.), surveyed 113,043 adults across all states. Findings: 101 million Indians have diabetes; 136 million have prediabetes; 254 million Indians are obese by Indian-specific criteria.

Indians are also predisposed to early, low-BMI diabetes because of the "thin-fat" body composition. At any given BMI, an average Indian has substantially more body fat and visceral fat than an average European, and beta-cell reserve is often lower from birth.

Layer onto this our food and festival calendar — high-carbohydrate staples, a chronic protein gap especially among lacto-vegetarians, late dinners after 9 pm, and a celebration culture that runs from Diwali to Karva Chauth to Navratri to Ramadan — and you have the perfect storm for metabolic disease.

For vegetarian Indian patients, the most important practical advice during titration is to protect protein intake while your appetite drops. Aim for 1.2–1.6 g of protein per kg of ideal body weight — roughly 60–90 g a day for most Indian adults. Paneer, dal-and-rajma combinations, tofu, soya chunks, Greek yoghurt, sprouted moong, and a daily glass of milk or buttermilk all help.

The big myths, cleared up

"It's a fad / a shortcut." It is neither. Semaglutide has been studied in tens of thousands of patients in over 30 randomised trials. The biology — copying a natural gut hormone — is well understood. What is true is that it is not a substitute for good food habits, sleep, and movement. Patients who treat it as the only lever rarely keep the weight off.

"Once you stop, you regain everything." Partially true. STEP-1's extension showed that people who stopped abruptly regained roughly two-thirds of what they had lost over the next year. But they did not return to baseline, and patients who continue treatment maintain results for at least four years (per SELECT).

"It causes thyroid cancer." The warning is based on rats, not humans. No clear signal has emerged in over a decade of human use, but anyone with a personal or family history of medullary thyroid cancer or MEN-2 syndrome must avoid it.

"Mounjaro and Ozempic are the same drug." No. Mounjaro is tirzepatide, which acts on two receptors (GLP-1 and GIP), and in head-to-head trials produced somewhat greater weight loss than semaglutide. Both are excellent medicines; which one suits you is a clinical decision.

What to do next

Ozempic, Wegovy, Rybelsus, and generic semaglutide are powerful, evidence-based medicines — not Instagram potions and not magic. Used in the right patient, with the right monitoring and the right lifestyle scaffolding, they reduce diabetes complications, prevent heart attacks and strokes, and produce levels of weight loss that until 2020 were only possible with surgery.

But they need a doctor. The dose has to be titrated, side effects managed, contraindications checked, and progress measured. Buying semaglutide off a wellness influencer's affiliate link is a fast route to nausea, dehydration, wasted money, and potentially serious harm.

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989–1002.
  2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844.
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
  4. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
  5. Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study. Lancet Diabetes Endocrinol. 2023;11(7):474–489.
  6. Misra A, et al. Revised Indian obesity guidelines. Diabetes Metab Syndr. 2025.